ARS Pharmaceuticals (SPRY) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• ARS Pharmaceuticals (NASDAQ:SPRY) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of ($0.42) per share and revenue of $12.92 million.
• The company reported ($0.35) earnings per share in its last quarterly results, matching analyst expectations, and achieved revenue of $7.97 million.
• Recent insider trading saw significant stock sales, with insiders selling 1,043,118 shares valued at over $18 million in the last three months.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect ARS Pharmaceuticals to post earnings of ($0.42) per share and revenue of $12.92 million for the quarter.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.35). ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%. The firm had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. On average, analysts expect ARS Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ARS Pharmaceuticals Stock Down 2.8%

ARS Pharmaceuticals stock traded down $0.50 during trading on Friday, reaching $17.18. 1,181,354 shares of the company's stock were exchanged, compared to its average volume of 1,213,610. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00. The company's 50-day moving average is $16.43 and its two-hundred day moving average is $14.10. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -107.37 and a beta of 0.90. ARS Pharmaceuticals has a 52-week low of $8.91 and a 52-week high of $18.90.

Insiders Place Their Bets

In other news, CFO Kathleen D. Scott sold 50,000 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $705,000.00. Following the sale, the chief financial officer owned 7,424 shares in the company, valued at approximately $104,678.40. This represents a 87.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total transaction of $1,451,862.90. Following the completion of the sale, the insider owned 89,613 shares in the company, valued at approximately $1,263,543.30. This trade represents a 53.47% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,043,118 shares of company stock worth $18,024,863. Company insiders own 33.50% of the company's stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals in the first quarter valued at approximately $140,000. Royal Bank of Canada increased its stake in shares of ARS Pharmaceuticals by 1,075.3% in the first quarter. Royal Bank of Canada now owns 18,547 shares of the company's stock valued at $234,000 after purchasing an additional 16,969 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of ARS Pharmaceuticals by 13.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 279,840 shares of the company's stock valued at $3,520,000 after purchasing an additional 32,526 shares during the period. Institutional investors and hedge funds own 68.16% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, July 26th. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.